The partnership will focus on the licensing, supply, and expected commercialization of Avicanna’s cannabinoid-based drug candidate Trunerox™, in Argentina in the second half 2022
TORONTO — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna’s proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients (“API”).
Through the partnership Avicanna will provide a non-exclusive license of the Company’s intellectual property related to its proprietary 10% cannabidiol (“CBD”) pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT.
The marketing authorization of the pharmaceutical preparation is expected to be approved during the second half of 2022 and is expected to be supported with claims related to treatment of epilepsy. The estimated patient population and market potential for epilepsy in Argentina is between 400,000 to 500,000 patients of which about 20,000 patients have refractory epilepsy. “We look forward to entering the Argentine market through a pharmaceutical pathway and to be doing so by delivering our proprietary formulations as solution to patients with unmet medical needs. We are rapidly expanding into the region with innovative and accessible cannabinoid-based pharmaceutical products and are doing so through partnership with reputable industry leaders,” stated Lucas Nosiglia, President of Avicanna LATAM.
Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:
- Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand, or Magisterial Preparations, these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The advanced formulary is marketed with consumer, patient and medical community education and training. Avicanna’s medical and wellness product portfolio also forms the foundation of the Company’s pharmaceutical pipeline with the contribution of the formulations that form the basis of the products as well as the data generated from sales and participation of the products in real world evidence studies.
- CBD Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura Earth™ brands, these registered, clinically tested, derma-cosmetic products include a portfolio of functional CBD topical products.
- Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
- Cannabis Raw Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™ brand, the Company’s raw material business has successfully completed sales to 11 countries. Aureus offers cannabis dried flower, standardized seeds, full spectrum extracts, and cannabinoid distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”) and other rare cannabinoids), and bulk formulations derived from hemp and cannabis cultivars through its sustainable, economical, and industrial-scale subsidiaries based in Colombia. The majority of the Aureus products are produced at Santa Marta Golden Hemp S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is also Good Agricultural and Collection Practices (“GACP”) certified and has United States Department of Agriculture (“USDA”) National Organic Program certification for its hemp cultivar.
SOURCE Avicanna Inc.
The Company posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the Company’s ability to register and commercialize its cannabinoid-based pharmaceutical preparations, expectations regarding the timing of the anticipated marketing authorization of the pharmaceutical preparation, the Company’s ability to register and get the necessary regulatory approvals in certain jurisdictions for its proprietary 10% CBD pharmaceutical drug that will be targeted for the treatment of epilepsy, whether claims related to treatment of epilepsy will be supported, and the Company’s plans for expansion into Argentina. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, the availability of licenses, approvals and permits, and the utility and application of certain drugs and products. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
- Mississippi House amends medical cannabis bill, returns to SenateThe House on Wednesday passed a Senate medical marijuana proposal, but only after changing the bill to lower the amount of cannabis a patient could get. The vote was 104-14 on the amended Senate Bill 2095.
- Cheech & Chef: Comedy legend fronts “stoner food” delivery service“With the pandemic, you want to go out,” Cheech Marin tells Profiles in Legalization, “but it’s tough to get into some places. So if you can order from them and have them deliver… Yay! Progress.”
- Florida’s growing medical cannabis program could lead to changesWith Florida’s medical marijuana program continuing to grow as more patients seek approval for marijuana cards, some state lawmakers in the 2022 session are pursuing changes to make it easier to access medical marijuana, raising concerns from some marijuana activists that physicians could be negatively impacted.
- Senate overwhelmingly passes Mississippi medical cannabisThe vote on Senate Bill 2095 was initially counted as 45-5, well beyond what would be considered a veto-proof majority, but subject to change as it was by use of morning roll call and senators could change their votes or check in through the end of the day.
- Ohio cannabis legalization group turns in additional signaturesThe Coalition to Regulate Marijuana Like Alcohol submitted 29,918 additional signatures in support of an initiated statute legalizing the adult use of marijuana to the Ohio Secretary of State’s office today.
- Senate vote on Mississippi medical cannabis bill expected Thursday. Here’s a look at the bill.After years of debate and hang-fire, a Mississippi medical marijuana program for people with chronic and debilitating illnesses inched forward Wednesday, with a Senate committee passing a bill along to the full chamber.
- Virginia lawmakers still at odds over resentencing for people in prison on cannabis chargesNearly a year after Virginia lawmakers voted to legalize possession of marijuana, they remain divided on what — if anything — to do about people currently imprisoned on marijuana charges.
- Opinion: We need Social Equity in all cannabis industries now“It’s time that we establish more robust social equity programs that allow all to thrive in this industry. It shouldn’t just be those who have institutional money or come from a position of privilege.”
- As clock ticks, headwinds build against Mississippi medical cannabisFor some time after the Supreme Court shot down a vote of the people to create a Mississippi medical marijuana, it appeared fait accompli that lawmakers would enact a program, per the “will of the voters.” That outcome is now in doubt.
- Oregon enforces new federal hemp rules for state growersHemp growers in the state will now need to abide by several new federal regulations that will be overseen by the Oregon Department of Agriculture. The changes come at a time of growing concerns over illegal marijuana operations in parts of southern Oregon.